Dilon's cart-based imaging systems offer results comparable to those of MRI images, but at a fraction of the cost.
MOUNTAIN VIEW, Calif., Aug. 3, 2016 /PRNewswire/ -- Based on its recent analysis of the Molecular Breast Imaging (MBI) market, Frost & Sullivan recognizes Dilon Technologies Inc., with the 2016 North American Frost & Sullivan Award for Technology Leadership. By creating a robust and clinically-effective imaging platform, Dilon has established MBI as a first-line diagnostic solution in the event of inconclusive mammogram results.
Logo - http://photos.prnewswire.com/prnh/20160802/395062LOGO
In 2004, Dilon's flagship product, Dilon 6800, became one of the first dedicated breast-specific gamma imaging (BSGI) devices. Within a decade, Dilon had entrenched itself as a technology leader, with a vibrant portfolio of diagnostic and surgical imaging devices including the Dilon 6800®, Dilon 6800 Acella®, and dual head GE's Discovery NM750b MBI System. The Dilon MBI solution houses state-of-the-art collimators, digital solid state technology, advanced algorithms that process the high-resolution images, and is available in single head or dual head configuration.
"Most gamma camera devices' design requires that there be a distance between the camera and the chest wall or that the camera be positioned for a lateral view in order to overcome the dead-space limitation," said Frost & Sullivan Senior Research Analyst Bhargav Rajan. "Through elegant product design, Dilon has significantly minimized the dead space, enabling its products to deliver images from a variety of angles, detect lesions as small as 1mm, and be operated the way conventional mammography is performed. Dilon 6800® has 15 x 20 cm detector, whereas Acella® has a larger detector of 20 x 25 cm to better accommodate and image patients with larger, denser breasts." Dilon's dual head Discovery NM750b Molecular Breast Imaging System has a detector of 16 x 24 cm.
The Dilon MBI systems are positioned as adjunct imaging approaches to mammography. As diagnostic tools, they aid in the early detection of cancer, evaluate the extent of cancerous growth, detect bilateral diseases, and help plan for surgeries. Dilon's GammaLoc® system is an accessory to the imaging systems; it uses MBI to locate suspicious lesions in the breast, which can then be biopsied using standard tools.
Dilon's systems can be employed in general imaging applications as well. They are adept at imaging the thyroid and parathyroid glands, lymph nodes, liver and gall bladder, and are suitable for orthopedic, cardiac, and neurological imaging. The various applications that Dilon's gamma cameras cater to are testimony to its robust performance and scalability.
Since its inception, Dilon has demonstrated solid business acumen in aligning with innovators and strategic partners to strengthen its product portfolio. In 2014, it acquired the assets and intellectual property (IP) of the Navigator line of gamma probes from Dynasil, an erstwhile leader in intra-operative surgical probes. Dilon Diagnostics has distribution agreements with industry giants Digirad Corporation and GE Healthcare, and is the exclusive international distributor of Digirad's nuclear imaging systems, Cardius™ and Ergo™.
"Dilon's MBI tests have excellent reimbursement coverage; the test is covered by a variety of public and private insurers across the world. This is expected to act as a powerful driver for adoption, especially as alternative options are known to be expensive," noted Rajan. "As of 2015, more than 200 Dilon systems have been installed in the United States, and the company is actively expanding its geographic footprint in Europe, Latin America, and Asia, specifically China."
Dilon Technologies Inc. has a formidable IP portfolio, with more than 25 domestic and international patents. In addition, it is actively scouting for cutting-edge technologies it can license and partners it can align itself with.
Overall, for driving future business value through its steadfast commitment to technology innovation, Dilon richly deserves the 2016 North American Frost & Sullivan Award for Technology Leadership.
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies that significantly impact both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Dilon Technologies Inc., (Newport, VA)
Dilon Technologies Inc. is a medical imaging company that specializes in designing and manufacturing molecular imaging solutions for breast imaging. Dilon offers a range of single and dual head Molecular Breast Imaging (MBI) systems. Dilon's MBI systems serve as high-resolution diagnostic imaging systems as well as image-guidance for biopsy and surgical procedures.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact:
Chiara Carella
P: +44 (0) 207.343.8314
F: 210.348.1003
E: chiara.carella@frost.com
